Can ketamine help with depression during cancer treatment?

Depression during cancer is common and often under-treated, and ketamine has drawn attention because it can lift mood within hours to days rather than the weeks standard antidepressants take. Early studies and a 2026 systematic review suggest it may help depression in cancer patients, but the evidence is still limited and the trials small. We consider it thoughtfully and always in coordination with a person's oncology team, not as a replacement for cancer care or standard mental health treatment.

Why does the speed of ketamine matter for someone with cancer?

Standard antidepressants often take four to six weeks to work. For someone facing a serious illness, weeks are precious, and depression can interfere with the strength and clarity needed to make treatment decisions, stay engaged with care, and be present with family. Ketamine's rapid effect is the main reason researchers have looked at it in this setting; the ability to shift a heavy mood quickly can matter differently when time itself feels short.

Is ketamine safe alongside chemotherapy and other cancer medications?

Safety here depends entirely on the individual and requires close coordination with the oncology team. Cancer patients are often on many medications and may have changes in blood pressure, liver or kidney function, and overall physical reserve that all factor into candidacy. We would review the full clinical picture, current treatments, and stability before considering ketamine, and we would want the oncologist involved. This is not a decision to make in isolation.

What is existential distress, and can ketamine address it?

Existential distress is the fear, demoralization, and loss of meaning that a serious diagnosis can bring, and it is distinct from ordinary clinical depression. Some palliative-care research has explored ketamine-assisted psychotherapy for this kind of suffering, and early real-world programs report it can be delivered safely. The evidence is preliminary, though, and this work is usually paired with skilled psychotherapy rather than infusions alone. We would be honest that this is an emerging area, not settled practice.

Does treating depression change cancer outcomes?

We would not claim ketamine treats cancer or changes survival. What we can say is that untreated depression is associated with worse engagement in care, more suffering, and greater strain on families. Relieving depression is worth doing for its own sake, because quality of life and the ability to stay connected to treatment and to loved ones matter deeply. That is the honest frame: better mood, not a cancer therapy.

Ketamine for Cancer-Related Depression

A cancer diagnosis reorders a life around scans, appointments, and hard decisions. In the middle of all that, mood often gets treated as an afterthought—something everyone assumes is a normal reaction to be endured rather than a condition to be treated. But depression during cancer is common, it’s serious, and it makes everything else harder.

It’s also frequently under-recognized, for the same reason post-illness depression usually is: people expect someone with cancer to feel down, so the clinical depression hiding inside the understandable sadness gets missed. That’s the backdrop against which ketamine has entered the conversation, and it’s worth walking through what the evidence actually supports and where it stops.

How Common Is Depression in Cancer

Depression and anxiety affect a substantial share of people going through cancer—estimates vary by cancer type and stage, but the numbers are high enough that oncology guidelines routinely call for screening. The mood symptoms aren’t only psychological. Cancer and its treatments drive inflammation, disrupt sleep, sap energy, and alter the same brain chemistry involved in mood regulation. So depression during cancer sits at the intersection of a real biological process and a genuinely frightening life situation.

Left untreated, it takes a toll well beyond suffering itself. Depression is linked with poorer engagement in treatment, worse quality of life, more difficulty making decisions, and heavier strain on caregivers. Relieving it is worth doing on its own terms.

Why the Speed Matters Here

Standard antidepressants, mostly SSRIs, remain a reasonable first step and help many people. Their limitation is timing: they often take four to six weeks to take hold. For someone in the thick of cancer treatment, that lag lands differently. Weeks are not abstract when you’re counting them, and a depression that flattens motivation and clouds thinking can interfere with exactly the strength and clarity a person needs to weigh options and stay present with the people they love.

Ketamine’s defining feature as an antidepressant is speed. It works through the glutamate system rather than serotonin, and relief can arrive within hours to days rather than weeks. We explain that mechanism in more depth in how ketamine works, but the practical point is simple: when time itself feels short, a treatment that can move a heavy mood quickly is worth understanding.

What the Research Actually Shows

Here’s where honesty matters. The interest is real and growing, but the evidence is early.

A systematic review published in 2026 examined ketamine for depression in adult cancer patients, framing it as a potential alternative to traditional antidepressants precisely because of its rapid action. Reviews like that pull together the available studies, and the available studies in this specific population are still limited in number and size. A signal worth pursuing is not the same as a settled answer, and the review reflects that.

Clinical trials underway reflect the same stage of the science. A study at the University of Zurich, sometimes called Keta-Care, is testing intranasal ketamine for depression and anxiety in palliative-care cancer patients, with results expected around the end of 2026. Other trials have looked at oral ketamine for anxiety in pancreatic cancer and at ketamine for cancer-related emotional distress. The takeaway from that landscape is that researchers consider the question important enough to study seriously, and that we don’t yet have large, definitive trials to point to.

Ketamine has emerged as a potential alternative to traditional antidepressants in cancer patients due to its rapid antidepressant action, though the evidence to date remains limited. — Summarized from a 2026 systematic review, Journal of Pain & Palliative Care Pharmacotherapy

It’s the same measured stance we take across the blog. Ketamine has a strong record in treatment-resistant depression generally, and cancer-related depression is often treatment-resistant by circumstance, so it’s reasonable to ask whether the benefit carries over. Asking is not the same as knowing, and we’d rather be clear about that line.

Existential Distress Is a Different Question

There’s a second thread in this research worth separating out, because it’s easy to blur with clinical depression. Serious illness can bring what clinicians call existential distress—fear of death, demoralization, a loss of meaning or dignity. That suffering is real, and it isn’t the same thing as a depressive episode, even when the two overlap.

Some palliative-care work has explored ketamine-assisted psychotherapy for this kind of distress. A 2026 report on a real-world palliative program described delivering ketamine-assisted psychotherapy to patients—most with cancer—safely, with only minor side effects and no serious adverse events across the sessions studied. Notably, that work pairs ketamine with skilled psychotherapy rather than using infusions alone; the medicine opens a window and the therapy does much of the work inside it.

We think this is a genuinely promising and humane area of inquiry, and also one where the evidence is preliminary and the practice specialized. We wouldn’t present ketamine as a proven treatment for existential distress. We’d name it as an emerging approach, usually integrated with therapy, and best pursued with clear eyes.

The Safety Conversation Comes First

Cancer changes the safety calculus in ways that make coordination non-negotiable. People undergoing treatment are frequently on many medications, and cancer and chemotherapy can affect blood pressure, liver and kidney function, blood counts, and overall physical reserve. Ketamine can transiently raise blood pressure and heart rate during an infusion, which is manageable and monitored in a stable adult but deserves real scrutiny in someone whose physiology is already under strain.

A few principles follow directly:

We would review the full clinical picture—cancer type and stage, current treatments, organ function, and every medication—before considering anything.
We would want the oncology team involved. This is not a decision to make around your cancer care, but alongside it.
Vital signs are monitored throughout each infusion, and the setting is calm and closely attended.
Ketamine is not a substitute for cancer treatment or for standard mental-health care—it’s one possible addition to a larger plan.

You can read more about how we think through candidacy in is ketamine therapy safe and about the situations where we say no in when we decline ketamine for a patient.

How We’d Approach It

If depression has settled in during cancer treatment and isn’t lifting, a careful evaluation is the starting point—never a fast yes or a fast no. Because a person going through cancer is often physically depleted and emotionally raw, the environment of an infusion matters even more than usual. Our sessions are unhurried, and Marla stays present throughout. Our therapy dogs, Walter White and Wilma, are part of the calm of the room, and for someone carrying a heavy diagnosis, that gentleness is not incidental.

The hours and days after each session, the neuroplastic window, are worth treating with intention too—rest, support, and continuity with a person’s broader care. And for many people, pairing ketamine with therapy, as the palliative-care programs do, makes the most sense. You can learn more about our general approach to depression treatment and about ketamine-assisted psychotherapy.

An Honest Bottom Line

Depression during cancer is common, damaging, and too often overlooked. Ketamine offers a different mechanism and a rapid effect, which is exactly why it’s being studied in this setting—and why the early findings, including a 2026 systematic review, are encouraging enough to take seriously. What we won’t do is overstate it. The evidence is still preliminary, the trials small, and safe use depends on close coordination with your oncology team. We would never suggest ketamine treats cancer; what it may do is help lift the depression that makes cancer harder to carry.

If you’re depressed during treatment, or watching someone you love disappear into a low mood alongside their diagnosis, we’d be glad to talk it through honestly—with a clear line between what the science supports and what it’s still working out.